Pieris Pharmaceuticals, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Note 8 - Income Taxes 1 (Tables)

Note 8 - Income Taxes 1 (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

		December 31,
		2023				2022
U.S. federal statutory rate			21.0	%			21.0	%
Uncertain tax position and interest			0.0				3.8
State and local taxes			4.0				(3.9	)
Permanent items			0.3				(1.0	)
Change in valuation allowance			(25.4	)			(16.3	)
Other			0.1				0.0
Effective income tax rate			0.0	%			3.6	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

		December 31,
		2023				2022
Deferred tax assets:
Royalty agreement liabilities		$	1,587			$	9,080
Net operating loss			9,179				7,850
Section 174 R&D capitalization			4,548				3,152
Accrued expenses and other			406				364
Orphan drug credit			199				199
Startup costs			95				104
Net deferred tax assets			16,014				20,749
Valuation allowance			(16,014	)			(20,749	)
Net deferred tax assets		$	—			$	—

Decrease (increase) in valuation allowance		$	4,735			$	(4,637	)